Navigation Links
Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma
Date:8/25/2014

, "I have been impressed by the results reported and updated from Dr. Rosenberg's group at the NCI. Particularly compelling are the frequency and the duration of the responses obtained in the difficult-to-treat patient population with relapsed, refractory lymphomas." Dr. Levy serves as a consultant to Kite and is helping to guide the Company in their upcoming clinical trials.

"We are greatly encouraged by the strong results we have seen from our joint lead clinical program with the NCI," commented Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer. "Based on this substantial progress, Kite plans to file an IND in the fourth quarter of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015."

Key Study Findings

The published clinical trial results relate to patients in the second cohort in the NCI's Phase 1-2a clinical trial of anti-CD19 CAR T cell therapy. The second cohort consists of 15 patients, including two retreated patients from a prior cohort, with advanced B cell malignancies, of which 13 were evaluable for responses, including seven with chemotherapy-refractory DLBCL.

Patients received a conditioning regimen of chemotherapy (cyclophosphamide and fludarabine) followed one day later by a single infusion of anti-CD19-CAR T cells. The CAR-expressing T cells were produced from each patient's own peripheral blood mononuclear cells (PBMCs), modified using a gammaretroviral vector encoding the CAR, as well as a CD28 costimulatory moiety.

Of the seven evaluable chemotherapy-refractory DLBCL patients, six showed a response (four complete remissions and two partial remissions), and one had stable disease.

Duration of ongoing complete respo
'/>"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006 x327
Burns McClellan
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Seamless Medical Systems Announces the Launch of SNAP Express Rx™ to Enhance Pharmacy Patient Engagement and Clinical Care Coordination
2. The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins
3. Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy
4. MedX Pharmacy Helps with Back to School Preparation
5. RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies
6. College of Pharmacy Has Banner Research Awards Year
7. Poland Pharmaceutical Industry Worth $15 Billion by 2020 Says a New Report Available at MarketOptimizer.org
8. Good Neighbor Pharmacy Invites Patients to Share Their "Good Neighbor Story"
9. Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia's Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program
10. Global Egg Phosphatidylcholine Market by Application (Cosmetic, Pharmaceutical, Dietary Supplements) is Expected to Reach USD 12.2 Million by 2020
11. Kirby Lester Pharmacy Robot Users: 97% Report Improved Operating Efficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl Institute ... Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment to ... front lines and throughout the experience movement, and provide information and research to ...
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, ... issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, is now ... new issue, Volume 6, Issue 2, as well as past issues of the ...
(Date:7/30/2015)... ... , ... Between 2012 and 2014 HIV infection rates rose from five to ... 17th. Those untreated heroin use disorders share their needles and spread the infection. Florida ... the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent due to ...
(Date:7/30/2015)... ... 30, 2015 , ... The New Jersey Innovation Institute (NJII), ... of Health, has received a $2.9 million grant from the Office of the ... Health and Human Services (HHS). NJII will help the Department of Health ensure ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... A Henry Ford Hospital study has found ... medication is managed for patients with heparin-induced thrombocytopenia ... Researchers found that patients treated by the anticoagulation ... drugs three times faster and were 32 percent ...
... alcohol during pregnancy can cause fetal alcohol syndrome (FAS) ... developing baby,s brain. Despite its harmful effects, pregnant mothers ... every 1000 babies are born with FAS, which causes ... features. How alcohol causes these effects is unclear, but ...
... HealthDay Reporter , MONDAY, Feb. 7 (HealthDay News) -- ... other mental health and developmental conditions, such as learning ... data on nearly 62,000 children aged 6 to 17 ... researchers found that those with ADHD had higher odds ...
... 7 (HealthDay News) -- The use of antipsychotic drugs to ... but measurable amount of brain tissue, a new study finds. ... average of three MRI brain scans over 7.2 years, for ... researchers then examined how four factors affected changes in brain ...
... , PHILADELPHIA - So-called barrier sites -- the skin, ... allergens, pollutants, viruses, bacteria, and parasites. Understanding how the ... for understanding such inflammatory diseases as asthma, psoriasis, IBD, ... body,s barriers. David Artis, PhD, professor of ...
... Dotinga HealthDay Reporter , MONDAY, Feb. 7 (HealthDay ... say you may be less likely to develop a tough-to-treat ... high alert. It,s not clear how this knowledge might ... lead author said the findings pave the way for further ...
Cached Medicine News:Health News:Using pharmacist-directed service improves quality of care for patients 2Health News:Figuring out fetal alcohol syndrome in fruit flies 2Health News:Most ADHD Kids Have Multiple Conditions, Study Says 2Health News:Schizophrenia Drugs May Spur Subtle Brain Tissue Loss 2Health News:Allergies Linked to Lower Brain Cancer Rate in Study 2Health News:Allergies Linked to Lower Brain Cancer Rate in Study 3
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... July 30, 2015  Cleveland Clinic President Wael ... address last month that industry is compelled to adopt ... gain the efficiencies—and develop the transformational innovations -- required ... comments were preceded by Doug Kohrs , past ... moderator, who stressed that industry must add "episode of ...
(Date:7/30/2015)... YORK , July 30, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Biosensors Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
...  Novation, the leading health care supply contracting company, today ... Summary Report, Winter 2012 .  This summary report highlights ... Forecast , including projected drug price inflation summary projections ... on purchase volume. Novation,s semi-annual Drug ...
... Minn., March 22, 2012 /PRNewswire-iReach/ -- ... emerging medical technology company, today announced the publication ... K. Potter, MD, LTC Brett A. Freedman, MD, ... National Military Medical Center, Bethesda, MD, describing their treatment ...
Cached Medicine Technology:Novation Releases its Drug Price Forecast for 2012-13 2Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma 2
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
... Anti-Nuclear Antibodies (ANAs) has long been an ... rheumatic diseases. The antigens used in their ... of human or animal nuclei, this has ... Antigens (ENAs). The most commonly measured ENA ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... (Ro), or SS-B (La)] in ... SS-B (La) antibodies aid in ...
... Diagnostic Automation, Inc. (DAI) ENA Profile Enzyme-Linked ... detection of antibodies in human serum to ... (La), Scl-70 and Jo-1 in a single ... are to be used as an aid ...
Medicine Products: